CD274 and non-small cell lung carcinoma: This concept has been tested in human trials and in early clinical studies the combination of ceralasertib (dosed intermittently) with durvalumab has been shown to be safe and tolerable with encouraging signs of clinical efficacy in a Phase II umbrella in advanced/metastatic NSCLC patients following platinum-doublet therapy and progressed on anti-PD-(L)1-containing immunotherapy (HUDSON trial NCT03334617)13.